Type of Submission

Poster

Keywords

MiR-146a, metformin, microRNA, inflammation

Abstract

Sjögren’s Syndrome (SjS) is an autoimmune disorder that affects secretory glands in the human body, restricting their function and causing extreme dryness in areas like the mouth and eyes. miR-146a is an anti-inflammatory microRNA that targets the NFκB activation pathway. Previous studies have shown that SjS patients have increased miR-146a expression, despite having high levels of inflammation. The objective of this study was to investigate whether metformin, a diabetes drug with a wide variety of effects and potential functions, reduces levels of miR-146a expression. Metformin is known to reduce inflammation by inhibiting the activation of NFκB. THP-1 human monocytes were treated with various concentrations of metformin ranging from 12.5uM to 200uM. The cells were treated for 24 hours before total RNA was isolated, and qRT-PCR was utilized to compare miR-146a expression in metformin-treated versus untreated cells. Our results showed a dose-dependent decrease of miR-146a expression in the presence of metformin. These results are reasonable since miR-146a expression is dependent on NFκB activation, and metformin is known to inhibit the activation of NFκB. Further studies will investigate metformin’s ability to suppress inflammation in varying conditions.

Campus Venue

Stevens Student Center

Location

Cedarville, OH

Start Date

4-12-2017 11:00 AM

End Date

4-12-2017 2:00 PM

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Download file contains only the abstract

Share

COinS
 
Apr 12th, 11:00 AM Apr 12th, 2:00 PM

Effect of Metformin on miR-146a Expression

Cedarville, OH

Sjögren’s Syndrome (SjS) is an autoimmune disorder that affects secretory glands in the human body, restricting their function and causing extreme dryness in areas like the mouth and eyes. miR-146a is an anti-inflammatory microRNA that targets the NFκB activation pathway. Previous studies have shown that SjS patients have increased miR-146a expression, despite having high levels of inflammation. The objective of this study was to investigate whether metformin, a diabetes drug with a wide variety of effects and potential functions, reduces levels of miR-146a expression. Metformin is known to reduce inflammation by inhibiting the activation of NFκB. THP-1 human monocytes were treated with various concentrations of metformin ranging from 12.5uM to 200uM. The cells were treated for 24 hours before total RNA was isolated, and qRT-PCR was utilized to compare miR-146a expression in metformin-treated versus untreated cells. Our results showed a dose-dependent decrease of miR-146a expression in the presence of metformin. These results are reasonable since miR-146a expression is dependent on NFκB activation, and metformin is known to inhibit the activation of NFκB. Further studies will investigate metformin’s ability to suppress inflammation in varying conditions.

 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.